Arkolith/Insider Trading/TSHA/Form 4

Nagendran Sukumar

President and Head of R&D, DirectorTaysha Gene Therapies, Inc. (TSHA) · full profile →Form 4 · filed Sep 12, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$646K
Net Open-Market Flow
-$646K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 10, 2025Option exercise(M)41K$0.70$29K1.2M
Sep 10, 2025Sell(S)200K$3.23$646K1.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 10, 2025Option exercise(M)41K—$0293K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-024369) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML